[EN] UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS<br/>[FR] DÉRIVÉS D'URÉE UTILISÉE EN TANT QUE MODULATEURS ALLOSTÉRIQUES DE CB1
申请人:RTI INT
公开号:WO2020264176A1
公开(公告)日:2020-12-30
Heteroaryl and aliphatic analogs of diarylurea-based cannabinoid 1 receptor (CB1 R) allosteric modulators of formula (I) are described. Exemplary analogs can provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1 R, such as substance abuse and obesity are described.
[EN] SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF<br/>[FR] ACTIVATEURS À PETITES MOLÉCULES DE NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE (NAMPT) ET LEURS UTILISATIONS
申请人:SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
公开号:WO2018132372A1
公开(公告)日:2018-07-19
Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
[EN] HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES DES PROTÉINES DU NOYAU DE L'HÉPATITE B
申请人:UNIV INDIANA RES & TECH CORP
公开号:WO2015138895A1
公开(公告)日:2015-09-17
ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
detectable products, phenylacetylene, phenylmethoxyacetylene (2), (E)-β-bromo-β-methoxy- styrene, and (Z)-β-bromo-α-methoxystyrene lie on discrete mechanistic paths and are not interconvertible under the reaction conditions. Comparable amounts of alkynyl and alkenyl ethers are formed by attack on carbon 1. The element effects for attack on halogen, K(Cl)/k(Br) ⋍ 0·4, and on carbon 1, k(Cl)/L(Br) ⋍ 1·6 are
A compound of the formula (I): wherein A is a hydrogen atom, an optionally substituted, unsaturated, N-containing heterocyclic group or a group of the formula (a): wherein R is an optionally substituted aryl group or an optionally substituted heterocyclic group; M is —(CH
2
)n-, —(CH
2
)n-O—(CH
2
)m-or —(CH
2
)n-NH—(CH
2
)m-, wherein n and m are independently 0, 1 or 2; Q is an optionally substituted cycloalkylene group, an optionally substituted arylene group or an optionally substituted divalent heterocyclic group; and the moiety of the formula (b): is an optionally substituted, unsaturated, mono-, di-, tri- or tetra-cyclic, N-containing heterocyclic group which may contain additional hetero atom(s) selected from the group consisting of nitrogen, oxygen and sulfur atoms as the ring member(s), its prodrug or a pharmaceutically acceptable salt thereof.